Xarelto Lawsuits

Background information on Xarelto lawsuits, settlements and litigation updates published between 2012 to 2018.

Important Update – January 2026: An Andexxa recall was announced on December 18, 2025, and the drug was subsequently removed from the U.S. market after regulators concluded it failed to reliably reverse life-threatening bleeding while increasing the risk of heart attack, stroke, dangerous blood clots, and related deaths.

Andexxa had been the only FDA-approved reversal agent available for bleeding events linked to Xarelto and Eliquis, raising new concerns for patients and providers following its withdrawal. In the wake of the recall, Andexxa lawsuits are now being investigated to determine whether the drug should ever have been approved or kept on the market.

Xarelto Lawsuit Overview

The Xarelto litigation involved claims that the anticoagulant rivaroxaban, manufactured by Bayer and marketed in the United States by Johnson & Johnson’s Janssen Pharmaceuticals, caused uncontrollable and life-threatening bleeding events.

Approved in 2011 as a convenient alternative to warfarin, Xarelto was widely prescribed to prevent strokes, deep vein thrombosis, and pulmonary embolism. However, patients soon began suffering severe internal bleeding, gastrointestinal hemorrhages, and brain bleeds, prompting allegations that the manufacturers failed to warn doctors and consumers about the absence of an effective reversal agent to stop its anticoagulant effects in emergencies.

Thousands of lawsuits were filed across the country accusing Bayer and Janssen of negligence, design defects, and misleading marketing. Plaintiffs argued that the companies knew from early clinical trials that Xarelto carried a heightened bleeding risk but aggressively promoted it as a safer, low-maintenance alternative to older blood thinners. The drug’s once-daily dosing and lack of required blood monitoring were key selling points, yet critics contended these features increased the danger of undiscovered complications.

The federal cases were consolidated into multidistrict litigation (MDL No. 2592) in the Eastern District of Louisiana for coordinated discovery and pretrial proceedings. Although several early bellwether trials resulted in defense verdicts, the companies later agreed in 2019 to a $775 million global settlement resolving roughly 25,000 claims.

Xarelto Litigation Updates

July 23, 2018: Court Issues New Case Selection Order in Xarelto MDL

The U.S. District Judge overseeing the Xarelto multidistrict litigation (MDL) issued an updated case management order to streamline remaining claims after early bellwether trials. The order focused on expediting resolution for thousands of pending lawsuits alleging the blood thinner caused severe and uncontrollable bleeding events.

May 4, 2017: Second Xarelto Bellwether Trial Moves Forward

A second federal bellwether trial began in the Xarelto MDL, testing claims that Johnson & Johnson and Bayer failed to adequately warn about the risks of life-threatening bleeding. The outcome was expected to influence settlement discussions across the litigation.

February 10, 2017: Xarelto Failure-to-Warn Claims Allowed to Proceed

The presiding judge rejected defense motions seeking to dismiss key failure-to-warn allegations in the Xarelto MDL. Plaintiffs were permitted to present evidence that the manufacturers knew of bleeding risks but did not update the drug’s label accordingly.

March 10, 2016: First Xarelto Bellwether Trial Set for April 24, 2017

The court scheduled the first federal bellwether trial to begin in spring 2017, involving claims from patients who suffered severe bleeding injuries. The trials were intended to gauge how juries might respond to evidence presented in thousands of similar lawsuits nationwide.

January 30, 2016: Summary Judgment Motions Filed in Xarelto MDL

Both plaintiffs and defendants submitted summary judgment motions ahead of upcoming bellwether trials. The filings sought rulings on key legal issues involving causation and failure-to-warn claims central to the litigation.

September 13, 2016: Xarelto State Bellwether Trials Planned in Philadelphia

State-level coordinated proceedings began moving forward in Pennsylvania, where hundreds of Xarelto lawsuits were consolidated as part of a mass tort program. Judges outlined plans to select early test cases parallel to the federal MDL.

August 9, 2016: Federal Bellwether Trials Delayed to 2017

The first Xarelto bellwether trials were postponed several months to allow additional discovery and expert depositions. Plaintiffs’ attorneys said the delay would help refine evidence related to internal company communications about bleeding risks.

April 25, 2016: Bellwether Trial Pool Narrowed to Key Representative Cases

The MDL judge finalized the list of bellwether cases to proceed to trial, choosing representative claims involving gastrointestinal bleeding, brain hemorrhages, and fatal clotting complications. The selection was meant to guide future settlement talks.

June 15, 2016: More Than 4,500 Xarelto Lawsuits Filed in Federal Courts

The number of Xarelto lawsuits swelled to over 4,500, with plaintiffs nationwide alleging that Johnson & Johnson and Bayer failed to provide adequate warnings about the drug’s uncontrollable bleeding side effects.

February 24, 2016: Bellwether Trial Selections Announced

The court released the list of first-round bellwether cases to move toward trial in 2017, covering various categories of bleeding injuries and fatalities. Each case was selected to reflect the broader allegations in the MDL.

January 12, 2016: Xarelto Bellwether Selection Order Finalized

A case management order outlined the criteria and schedule for selecting bellwether cases to represent the thousands of claims pending in federal court. The move aimed to streamline pretrial proceedings and discovery.

July 29, 2015: More Than 2,000 Xarelto Lawsuits Filed Nationwide

Plaintiffs reported a rapid increase in filings, with over 2,000 cases consolidated in the MDL. The court began organizing discovery and preparing for early test trials to evaluate liability evidence.

April 16, 2015: Xarelto Bellwether Selections Underway

Federal and state judges coordinated the bellwether selection process for both the MDL in Louisiana and the Pennsylvania mass tort program. Early discovery focused on warning label adequacy and risk mitigation efforts by the manufacturers.

February 4, 2015: Xarelto Injury Categories Defined by Court Order

The presiding judge issued an order grouping claims into categories such as gastrointestinal bleeding, intracranial hemorrhage, and fatal bleeding events. The classification was intended to guide discovery and bellwether selection.

December 23, 2014: Xarelto Bellwether Selection Process Outlined

Attorneys from both sides presented proposals for selecting the first bellwether cases. The judge approved a discovery schedule and outlined trial sequencing for 2016.

October 15, 2014: Xarelto Bellwether Trials Scheduled

The court established a detailed plan for early trials to evaluate evidence and liability claims. The bellwether process aimed to promote potential settlements before full litigation of thousands of individual cases.

September 11, 2014: Discovery Phase Begins in Federal Xarelto MDL

Attorneys commenced document exchanges and depositions involving company executives and experts. The discovery focused on whether the drugmakers properly tested and warned about bleeding risks.

August 1, 2014: Xarelto “Science Day” Scheduled for Expert Presentations

The MDL court organized a “Science Day” to allow both sides to present scientific evidence about how Xarelto works and its associated bleeding risks. The session was designed to educate the judge before substantive rulings on expert testimony.

June 18, 2014: Filing Order Established in Xarelto MDL

Judge Eldon E. Fallon issued a pretrial order establishing filing and response protocols for all future cases centralized in the Eastern District of Louisiana. The move standardized procedures across thousands of claims.

May 22, 2014: Leadership Attorneys Appointed in Federal Xarelto Litigation

The MDL court appointed a group of plaintiffs’ attorneys to oversee discovery, coordinate pretrial proceedings, and represent all claimants in negotiations and hearings.

April 3, 2014: Xarelto Lawsuits Consolidated in Pennsylvania Mass Tort

In addition to the federal MDL, the Philadelphia Court of Common Pleas created a coordinated mass tort docket to handle state-level Xarelto claims involving similar allegations of dangerous bleeding side effects.

February 12, 2014: Plaintiffs and Defendants Meet Judge Fallon for Status Conference

Attorneys met with the presiding judge to review case management protocols and deadlines in the newly centralized MDL. The court emphasized cooperation to expedite discovery and bellwether planning.

February 5, 2014: Xarelto MDL Centralized in Eastern District of Louisiana

The U.S. Judicial Panel on Multidistrict Litigation consolidated all federal Xarelto lawsuits before Judge Eldon Fallon in Louisiana to streamline pretrial proceedings and avoid inconsistent rulings.

January 30, 2014: Oral Arguments Heard on MDL Centralization

The JPML held arguments to determine whether the growing number of Xarelto lawsuits warranted centralization. Both sides presented views on the most appropriate venue for coordinated proceedings.

January 15, 2014: Defendants Oppose Xarelto MDL Formation

Drugmakers Bayer and Johnson & Johnson opposed efforts to centralize lawsuits, arguing that individualized medical circumstances made consolidation unnecessary. Plaintiffs countered that centralization would promote efficiency.

December 23, 2013: Hearing Scheduled on Xarelto MDL Motion

The Judicial Panel on Multidistrict Litigation scheduled oral arguments to consider whether Xarelto lawsuits should be consolidated in federal court.

December 4, 2013: Plaintiffs File Motion to Centralize Xarelto Lawsuits

The first formal request was filed with the JPML seeking consolidation of Xarelto bleeding lawsuits into a single federal MDL, citing growing numbers of claims and overlapping allegations.

Xarelto Settlements and Verdicts

Xarelto March 25, 2019: Xarelto Global Settlement Reached to Resolve All Remaining Lawsuits

Johnson & Johnson and Bayer agreed to pay $775 million to settle roughly 25,000 Xarelto lawsuits filed nationwide. The agreement came after years of bellwether trials and appeals, bringing an end to claims alleging the blood thinner caused uncontrollable bleeding and lacked an effective reversal agent.

August 1, 2018: Jury Returns Defense Verdict in Latest Xarelto Bellwether Trial

A federal jury once again sided with Bayer and Johnson & Johnson, finding the companies were not liable for a plaintiff’s gastrointestinal bleeding injuries. The verdict marked another win for the defense in the multidistrict litigation after multiple prior bellwether losses for plaintiffs.

June 14, 2018: Pennsylvania Appeals Court Overturns $28 Million Xarelto Verdict

A state appeals court vacated a $28 million award previously granted to a Pennsylvania plaintiff who alleged severe internal bleeding injuries. The ruling determined that improper jury instructions warranted a new trial, dealing a setback to plaintiffs seeking leverage in settlement talks.

February 13, 2018: Jury Awards $27.8 Million to Xarelto Plaintiff in Philadelphia Trial

A Philadelphia jury found in favor of the plaintiff, awarding $27.8 million in damages over gastrointestinal bleeding linked to Xarelto. Jurors concluded the manufacturers failed to adequately warn about the risk of serious bleeding injuries associated with the anticoagulant.

August 8, 2017: Mississippi Jury Sides with Defendants in Xarelto Bellwether Trial

A federal jury in Mississippi issued a defense verdict for Bayer and Johnson & Johnson, rejecting claims that Xarelto’s labeling was inadequate. The decision was the third straight bellwether win for the drugmakers in the MDL proceedings.

June 13, 2017: Plaintiffs Seek Retrial After Consecutive Defense Wins

Plaintiffs’ attorneys filed motions for a new trial following back-to-back defense verdicts, arguing that critical evidence was excluded from juries in the first two bellwether cases. The court took the motions under consideration as the litigation continued.

May 4, 2017: Second Federal Jury Returns Defense Verdict in Xarelto Bellwether Case

The second Xarelto bellwether trial ended in favor of the drug manufacturers, who successfully argued that the bleeding risks were clearly outlined on the label. The verdict reaffirmed earlier outcomes and weakened plaintiffs’ early trial momentum.

May 3, 2017: First Xarelto Bellwether Trial Ends in Defense Verdict

The inaugural federal bellwether trial concluded with a win for Bayer and Johnson & Johnson after jurors found insufficient proof that the companies failed to warn about bleeding risks. The case served as the opening test for thousands of similar lawsuits nationwide.

Xarelto Research and Reports

April 23, 2019: Study Links Xarelto to Increased Brain Bleeding Risk

A new study identified higher rates of intracranial bleeding among Xarelto users compared to patients on other anticoagulants. Researchers urged stronger monitoring and patient screening protocols to reduce potentially fatal complications.

May 3, 2018: Blood Thinner Deaths Continue to Rise, ISMP Report Warns

The Institute for Safe Medication Practices found that Xarelto remained among the top drugs linked to serious injuries and deaths in the U.S., citing thousands of reports involving uncontrollable bleeding and hemorrhagic strokes.

April 4, 2017: Xarelto Shows Comparable Safety in Limited FDA Analysis

An FDA evaluation of Xarelto’s clinical trial data reaffirmed its overall bleeding profile but acknowledged that flawed testing devices may have skewed early results. The findings renewed debate over whether the drug was approved on incomplete evidence.

January 17, 2017: Blood Testing Device Problems Undermine Xarelto Trials

Investigators discovered that a faulty blood testing device used during key Xarelto clinical trials may have produced inaccurate safety data. Critics argued this raised concerns about the drug’s approval process and real-world bleeding risks.

September 26, 2016: ISMP Highlights Thousands of Xarelto Injury Reports

A quarterly ISMP report revealed that Xarelto continued to rank among the most frequently cited drugs in adverse event filings, with reports of gastrointestinal bleeding, hemorrhages, and death continuing to climb.

April 18, 2016: Questions Persist Over Xarelto Clinical Trial Data

Analysts raised new doubts about the reliability of the ROCKET-AF trial, which supported Xarelto’s approval, suggesting missing data may have underestimated bleeding risks. Regulators reviewed whether flawed methodologies compromised patient safety.

December 7, 2015: Xarelto Clinical Trial Oversight Concerns Emerge

Critics questioned the quality control and data handling of Xarelto’s clinical research, arguing that the results may have misrepresented safety outcomes. The findings spurred renewed calls for post-market studies.

September 22, 2015: Gastrointestinal Bleeding Risks Higher with Xarelto and Pradaxa

A large comparative study found that Xarelto and Pradaxa users faced significantly higher rates of gastrointestinal bleeding than patients taking older anticoagulants like warfarin. Researchers recommended tighter prescribing oversight.

February 25, 2015: Experts Question Xarelto Dosing Logic

Researchers expressed concern that Xarelto’s once-daily dosing regimen may not maintain consistent anticoagulant levels, potentially increasing the risk of clotting or bleeding events between doses.

December 9, 2014: Problems Found in Key Xarelto Study

The New England Journal of Medicine highlighted issues in the primary clinical trial supporting Xarelto’s approval, including use of a malfunctioning blood testing device that may have skewed results.

August 14, 2014: Xarelto Bleeding Risk Study Identifies Higher Injury Rates

A peer-reviewed study showed that patients taking Xarelto had increased rates of serious bleeding injuries compared to other factor Xa inhibitors. Researchers called for closer patient monitoring and physician education.

May 12, 2014: U.K. Regulators Restrict Xarelto for Certain Patients

The U.K. National Health Service advised against prescribing Xarelto for some older patients and those with kidney impairment after reviewing safety data linking the drug to fatal bleeding events.

March 18, 2014: Xarelto Monitoring Study Suggests Improved Safety with Testing

Researchers found that periodic blood monitoring could improve patient safety for those taking Xarelto, countering manufacturer claims that the drug required no routine testing.

June 24, 2013: Study Explores Reversal Agents for New Blood Thinners

Medical researchers began investigating potential antidotes for newer anticoagulants like Xarelto and Pradaxa. Early studies suggested several candidates capable of reversing bleeding effects during emergencies.

March 12, 2013: Xarelto and Pradaxa Lead in Adverse Event Reports

An FDA safety analysis showed that Xarelto and Pradaxa were associated with the highest number of serious bleeding incidents among all anticoagulants. Regulators said the data underscored the need for stronger safety warnings.

January 29, 2013: FDA Rejects Expanded Xarelto Use Due to Bleeding Risks

Federal regulators declined to approve a new indication for Xarelto after studies revealed elevated bleeding risks compared to other treatments. The rejection delayed the drug’s expansion into additional cardiovascular uses.

July 16, 2012: Public Citizen Urges Consumers to Avoid Xarelto and Pradaxa

The advocacy group Public Citizen advised patients to avoid both Xarelto and Pradaxa due to high rates of severe bleeding and the absence of reversal agents. The group petitioned the FDA for stronger warnings and usage restrictions.

April 19, 2012: FDA Rejects Xarelto for Acute Coronary Syndrome

The FDA declined to approve Xarelto for treatment of acute coronary syndrome, citing concerns over increased bleeding events during clinical testing.

January 11, 2012: Proposed Study to Develop Xarelto Antidote Announced

Researchers outlined plans for an antidote study aimed at reversing the blood-thinning effects of Xarelto and similar medications. The project was designed to address the growing number of fatal bleeding incidents reported.

July 20, 2011: Reports of Blood Clots Among Xarelto Users Surface

Health regulators began receiving adverse event reports of blood clots among patients prescribed Xarelto shortly after its release. The findings prompted calls for additional safety monitoring.

December 15, 2011: Study Warns of Health Risks from Pradaxa, Xarelto, and ASA

An early analysis found that patients taking new-generation blood thinners faced heightened risks of bleeding and other cardiovascular side effects compared to traditional anticoagulants.

Xarelto Lawsuit Examples

February 8, 2018: Xarelto Hematuria Lawsuit Filed Over Severe Bleeding

A patient filed a claim alleging that Xarelto caused severe hematuria, or blood in the urine, leading to hospitalization and long-term kidney complications. The lawsuit accused Bayer and Johnson & Johnson of failing to warn about bleeding risks.

January 26, 2018: Lawsuit Alleges Xarelto Caused Life-Threatening Anemia

A woman filed suit after suffering extreme blood loss and anemia while taking Xarelto. Her complaint claimed the manufacturers misrepresented the drug’s safety and overstated its benefits over older anticoagulants.

September 22, 2017: Aortic Aneurysm Linked to Xarelto in New Lawsuit

A man alleged that Xarelto contributed to an aortic aneurysm and subsequent bleeding complications. The lawsuit accused the drugmakers of ignoring evidence that the anticoagulant could cause fatal internal hemorrhaging.

August 12, 2016: Subdural Hematoma Lawsuit Filed Over Xarelto Use

A wrongful death lawsuit claimed that Xarelto led to a fatal subdural hematoma after minor head trauma. The filing alleged that patients were not warned that no reversal agent existed at the time to stop the bleeding.

April 25, 2016: Patient Suffers Pericardial Effusion After Xarelto Treatment

A Texas man filed suit after developing a pericardial effusion—fluid buildup around the heart—while taking Xarelto. The complaint claimed inadequate labeling about cardiovascular bleeding dangers.

January 6, 2016: Stomach Bleeding Lawsuit Filed Against Xarelto Makers

A woman filed a lawsuit alleging that Xarelto caused a severe gastrointestinal bleed that required emergency surgery. The case alleged the companies failed to warn about the heightened risk among elderly users.

November 16, 2015: Intracranial Bleeding Lawsuit Highlights Xarelto Brain Hemorrhage Risks

A plaintiff claimed that Xarelto led to a sudden intracranial bleed, resulting in permanent neurological damage. The lawsuit cited failures to properly instruct doctors about monitoring and reversal limitations.

September 9, 2015: Gastrointestinal Bleeding Lawsuit Filed Over Xarelto Use

A man who took Xarelto for atrial fibrillation claimed the drug caused internal bleeding and required blood transfusions. The lawsuit alleged the manufacturers promoted the drug as safer than warfarin despite evidence of higher GI bleeding risk.

June 25, 2015: Canadian Lawsuits Filed Over Xarelto Bleeding Injuries

A series of class action lawsuits were filed in Canada alleging that Xarelto users suffered serious and sometimes fatal bleeding events. Plaintiffs claimed Bayer and Johnson & Johnson failed to disclose the full extent of the risk.

October 24, 2014: Lawsuit Says Xarelto Warnings on Hemorrhage Risk Were Inadequate

A new complaint alleged that the labeling for Xarelto failed to include sufficient warnings about the risk of internal hemorrhage and the absence of an antidote, resulting in a patient’s hospitalization.

September 12, 2014: Xarelto Bleeding Risk Lawsuit Filed After Fatal Injury

A family filed a wrongful death lawsuit claiming a loved one died from uncontrolled bleeding while using Xarelto. The lawsuit accused the manufacturers of negligence and misrepresentation of the drug’s safety profile.

August 18, 2014: Wrongful Death Lawsuit Filed Over Xarelto Bleeding Event

A Georgia family alleged that Xarelto caused fatal bleeding complications and that the drugmakers failed to warn about the dangers of prescribing the anticoagulant without regular blood monitoring.

July 29, 2014: Wrongful Death Claim Links Xarelto to Fatal Bleed

Another wrongful death lawsuit was filed by surviving family members who claimed that the lack of a reversal agent made the drug unreasonably dangerous for elderly patients.

May 6, 2014: Multiple Xarelto Bleeding Lawsuits Filed Nationwide

Dozens of new cases were filed across the country alleging that Xarelto caused uncontrollable internal bleeding and death. Plaintiffs asserted the manufacturers downplayed the severity of known bleeding risks.

March 20, 2014: Internal Bleeding Lawsuit Filed Over Xarelto Use

A woman filed one of the first Xarelto lawsuits after suffering severe internal bleeding. Her case alleged that the anticoagulant’s risks outweighed its purported benefits and that safer alternatives were available.